MedTrace Logo

A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants

NCT04493255 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2021-02-04

No results posted yet for this study

Summary

The primary objective of this study is to determine the pharmacokinetics (PK) and excretion of E7090 and its metabolites in healthy male participants. Also, to assess the safety and tolerability of a single dose of E7090 in healthy male participants.

Conditions

  • Healthy Volunteers

Interventions

DRUG

[14C]E7090

\[14C\]E7090, oral capsule.

Sponsors & Collaborators

  • Eisai Limited

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-09
Primary Completion
2020-10-21
Completion
2020-10-21

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04493255 on ClinicalTrials.gov